Value of detection of serum human epididymis secretory protein 4 and carbohydrate antigen 125 in diagnosis of early endometrial cancer of different pathological subtypes

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 1239-1243

  Liu, Xingui ^a   Zhao, Fengting ^a   Hu, Linli ^a   Sun, Yingpu ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

Detection of CA125; Endometrial cancer; HE4

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; HUMAN EPIDIDYMIS SECRETORY PROTEIN 4; SECRETORY PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CA 125 ANTIGEN BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENDOMETRIOID ADENOCARCINOMA; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPLORATORY RESEARCH; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN EPIDIDYMIS SECRETORY PROTEIN 4 BLOOD LEVEL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY;

EID: 84930641331     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S81853     Document Type: Article

References (13)

1. Meizhen J, Haiyan J, Fengyi H, et al. Value of hysteroscopy and dilatation and curettage in preoperative diagnosis of endometrial carcinoma. Chin Pract Med. 2014;(22):34–36.
2. Xiaohui S, Jiangtao F, Yan L, et al. Preliminary research of serum YKL-40 in the diagnosis of endometrail carcinoma. J Pract Obstet Gynecol. 2011;27(2):121–124.
3. Bin C, Xiaowei X, Xuelian L, et al. The application of human epididymis protein 4 in diagnosis of endometrial cancer. J Pract Obstet Gynecol. 2012;28(5):354–356.
4. Kirchhoff C, Habben I, Ivell R, et al. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular protease inhibitors. J Biol Reprod. 1991;45(2):350–357.
5. Hough CD, Baust CA, Pizer ES, et al. Large-scale serial analysis of gene expression reveals genes deferentially expressed in ovarian cancer. Cancer Res. 2000;60(31):6281.
6. Schummer M, Ng WV, Bumgarner RE, et al. Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes over expressed in ovarian carcinomas. Gene. 1999;23(2):375.
7. Yuping F, Guohua T. Value of combined detection of HE4 and CA125 in early diagnosis of ovarian cancer. Labeled Immunoassays Clin Med. 2010;17(6):368.
8. Xia C, Ping Z, Xiaoyan L. Relationship between the serum human epididymis secretory protein 4 and clinical pathological features in patients with epithelial ovarian cancer. Labeled Immunoassays Clin Med. 2010;17(6):365–367.
9. Li J, Dowdy S, Tipton T, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn. 2009;9(6): 555–566.
10. Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumors from ovarian endometriotic cysts. Br J Cancer. 2009;100(8):1315–1319.
11. Jianwei Z. Detection of serum HE4 combined with CA125 in diagnosis of endometriosis and pelvic malignancy. Shandong Med J. 2014;54(25):84–85.
12. Rahaman J, Steiner N, Hayes MP, Chuang L, Fishman D, Gretz Iii H. Chemotherapy for gynecologic cancers. Mt Sinai J Med. 2009; 76(6):577–588.
13. Nosov V, Su F, Amneus M, et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol. 2009;200(6): 639. e1–639. e5.